Evidence map›Paper›PMID 37605371›Full record

ArticlemAbs

Monte Carlo Thompson sampling-guided design for antibody engineering.

Taro Kakuzaki, Hikaru Koga, Shuuki Takizawa, Shoichi Metsugi, Hirotake Shiraiwa, Zenjiro Sampei, Kenji Yoshida, Hiroyuki Tsunoda, Reiji Teramoto

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Taro KakuzakiResearch Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan.
Hikaru KogaResearch Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan.
Shuuki TakizawaResearch Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan.
Shoichi MetsugiResearch Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan.
Hirotake ShiraiwaResearch Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan.
Zenjiro SampeiResearch Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan.
Kenji YoshidaResearch Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan.
Hiroyuki TsunodaResearch Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan.
Reiji TeramotoResearch Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan.
Chugai Pharma (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies are one of the predominant treatment modalities for various diseases. To improve the characteristics of a lead antibody, such as antigen-binding affinity and stability, we conducted comprehensive substitutions and exhaustively explored their sequence space. However, it is practically unfeasible to evaluate all possible combinations of mutations owing to combinatorial explosion when multiple amino acid residues are incorporated. It was recently reported that a machine-learning guided protein engineering approach such as Thompson sampling (TS) has been used to efficiently explore sequence space in the framework of Bayesian optimization. For TS, over-exploration occurs when the initial data are biasedly distributed in the vicinity of the lead antibody. We handle a large-scale virtual library that includes numerous mutations. When the number of experiments is limited, this over-exploration causes a serious issue. Thus, we conducted Monte Carlo Thompson sampling (MTS) to balance the exploration-exploitation trade-off by defining the posterior distribution via the Monte Carlo method and compared its performance with TS in antibody engineering. Our results demonstrated that MTS largely outperforms TS in discovering desirable candidates at an earlier round when over-exploration occurs on TS. Thus, the MTS method is a powerful technique for efficiently discovering antibodies with desired characteristics when the number of rounds is limited.

Indexed as

AntibodiesProtein EngineeringBayes TheoremMonte Carlo MethodAntibodiesAntibody engineeringBayesian optimizationmachine learningMonte Carlo methodprotein engineeringThompson sampling

Identifiers

PMID37605371
PMCPMC10446805
OpenAlexW4386045844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.